CASE REPORTSComplete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma efficacy and tolerability in an elderly patientSponghini, Andreaa; Patrucco, Federicaa; Giorgione, Robertob; Farinelli, Pamelab; Zottarelli, Francescab; Rondonotti, Davida; Savoia, PaolabAuthor Information aDepartment of Oncology, Maggiore Hospital bDepartment of Health Sciences, University of Eastern Piedmont, Novara, Italy Correspondence to Paola Savoia, MD, Department of Health Science, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy Tel: +39 032 137 33387; fax: +39 032 137 33586; e-mail: email@example.com Received December 12, 2016 Accepted April 18, 2017 Anti-Cancer Drugs: August 2017 - Volume 28 - Issue 7 - p 808-810 doi: 10.1097/CAD.0000000000000515 Buy Metrics Abstract The advent of immune checkpoint inhibitors anti-PD-1/PD-L1 has delivered new and effective treatment options with proven clinical benefits for patients affected by metastatic melanoma. The 30–40% of treated patients experience an objective tumour regression, with a significantly prolonged survival and an improved quality of life. Here, we report a case of a 75-year-old Caucasian woman affected by a massive cutaneous metastasis from a BRAF wild-type melanoma who experienced multiple relapses after surgery and repeated electrochemotherapy treatments. A poor response was observed after systemic therapy with ipilimumab, whereas a marked reduction in the lesion size was obtained during the treatment with nivolumab, with an objectively complete response after 6 months. Therapy was well tolerated, without immune-related side effects. During treatment, LDH levels decreased up to the standard values. Our experience confirms the good efficacy and the safety of anti-PD-1 nivolumab for the treatment of relapsed or refractory massive skin lesions, also in elderly patients. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.